Unlocking the power of the immune system

Nectin Therapeutics is a pre-clinical biotechnology company developing next generation cancer immunotherapeutics. The Company has a diverse pre-clinical pipeline of immune checkpoint inhibiting monoclonal antibodies and CAR-T cells targeting key regulatory proteins of the Nectin family. Immune checkpoint inhibitors developed by Nectin Therapeutics have a potential of becoming stand-alone cancer immunotherapies as well as enhancing the activity of currently used immune-oncological drugs.